Experimental retrograde adriamycin trigeminal sensory ganglionectomy

J Neurosurg. 1988 Nov;69(5):760-5. doi: 10.3171/jns.1988.69.5.0760.

Abstract

Direct destruction of the sensory ganglion or its root, by either surgical transection or injection of phenol, has been employed as preferred treatment for a variety of neuralgic pain syndromes. In this report, the suicide axoplasmic transport of adriamycin is described as a novel approach to sensory ganglionectomy. When injected into a branch of the trigeminal nerve in the cat, adriamycin was swiftly transported by way of retrograde axoplasmic flow to the sensory neurons parental to the injected nerve, where adriamycin-specific autofluorescence was observed. Trigeminal sensory evoked potentials became unobtainable 24 to 48 hours after injection of adriamycin in concentrations of 1% to 10%. The sensory neurons underwent subacute degeneration within a week due to the delayed action of adriamycin, and consequently the primary afferents degenerated in a restricted projection field of the brain-stem trigeminal sensory nuclei. These results indicate that retrograde axoplasmic transport of adriamycin is a unique approach to noninvasive sensory ganglionectomy with strict, albeit simple, safe targeting of sensory neurons and little likelihood of regeneration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Axons / ultrastructure
  • Cats
  • Doxorubicin / therapeutic use*
  • Evoked Potentials, Somatosensory
  • Female
  • Fluorescence
  • Ganglia / pathology*
  • Ganglia / physiopathology
  • Ganglionectomy / methods*
  • Male
  • Nerve Degeneration
  • Neural Conduction / drug effects
  • Neurons, Afferent / drug effects*
  • Osmolar Concentration
  • Palliative Care
  • Sensation / physiology*
  • Trigeminal Nerve / pathology*
  • Trigeminal Nerve / physiopathology
  • Trigeminal Nucleus, Spinal / pathology

Substances

  • Doxorubicin